期刊
BIOMARKERS IN MEDICINE
卷 12, 期 8, 页码 881-890出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2018-0155
关键词
biomarker; CA 19-9; CEA; CRC; HSP90 alpha
资金
- National Science Foundation of China [81371886, 81672104]
- Science and Technology Development Project of Shandong Province [2016GSF201211, 2015GSF118125]
Aim: We investigated HSP90a as screening biomarker for early colorectal cancer (CRC). Methods & results: Seventy-seven CRC patients and 78 healthy controls were enrolled. Plasma HSP90a was significantly higher in CRC patients than in healthy controls (p < 0.05). levels were higher in late (stages III and IV) CRC than in early (stages I and II) CRC (p = 0.022). HSP90a conferred an advantage in the diagnosis of early CRC. Combination of HSP90a and carcinoembryonic antigen improved the diagnostic sensitivity (84.4%) and specificity (89.5%) for CRC (area under the curve: 0.968); for early CRC, the sensitivity was 82.5% and specificity was 89.5% (area under the curve: 0.955). Conclusion: HSP90 is a potential biomarker for the diagnosis of early CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据